The administration of PARP inhibitors had anti-tumor efficacy in KEAP1 mutant NSCLC and this was further augmented with the addition of STING agonist, providing a rationale for the use of PARP inhibitors in NSCLC with BRCAness phenotype due to the KEAP1 mutation. This evidence concerns the gene STING1 and non-small cell lung carcinoma.